Aimei Health Tech | 10-Q: FY2025 Q2 EPS: USD 0.09

EPS: As of FY2025 Q2, the actual value is USD 0.09.

Segment Revenue

• Interest Earned on Assets Held in Trust: $466,574 for the three months ended June 30, 2025, and $918,206 for the three months ended June 30, 2024. For the six months ended June 30, 2025, interest earned was $1,064,650, compared to $1,827,338 for the six months ended June 30, 2024.

Operational Metrics

• Net Income: $424,970 for the three months ended June 30, 2025, compared to $609,092 for the three months ended June 30, 2024. For the six months ended June 30, 2025, net income was $609,632, compared to $1,364,592 for the six months ended June 30, 2024.
• Formation and Operating Costs: $41,604 for the three months ended June 30, 2025, compared to $309,114 for the three months ended June 30, 2024. For the six months ended June 30, 2025, formation and operating costs were $455,018, compared to $462,746 for the six months ended June 30, 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $425,759 for the six months ended June 30, 2025, compared to - $423,212 for the six months ended June 30, 2024.
• Net Cash Provided by Investing Activities: $30,337,800 for the six months ended June 30, 2025, compared to $0 for the six months ended June 30, 2024.
• Net Cash Used in Financing Activities: - $29,938,111 for the six months ended June 30, 2025, compared to $0 for the six months ended June 30, 2024.

Unique Metrics

• Cash Held in Trust Account: $44,511,399 as of June 30, 2025, compared to $73,784,549 as of December 31, 2024.
• Total Assets: $44,556,037 as of June 30, 2025, compared to $73,814,933 as of December 31, 2024.
• Total Liabilities: $2,903,966 as of June 30, 2025, compared to $1,506,994 as of December 31, 2024.
• Total Shareholders’ Deficit: - $2,859,328 as of June 30, 2025, compared to - $1,476,610 as of December 31, 2024.

Future Outlook and Strategy

• Core Business Focus: The company aims to consummate a business combination by September 6, 2025, with a focus on healthcare innovation, targeting small cap companies in North America, Europe, and the Asia Pacific regions developing assets in biopharmaceutical, medical technology/medical device, and diagnostics space.
• Non-Core Business: The company has extended the timeframe to consummate a business combination nine times by an additional one month each time, with the latest extension until September 6, 2025.
• Priority: The company is focused on completing the proposed business combination with United Hydrogen Group Inc. by September 30, 2025, and has entered into a definitive Business Combination Agreement with United Hydrogen Group Inc.